Freeslate Launches CM Protégé PharmD System for Solid Form and Solubility Screening in Drug Development

Share Article

Product family expansion makes automation more accessible to broader customer base for preformulation chemistry

The CM Protégé PharmD platform is the next evolution in our long history of providing systems for crystallization and solubility screens and demonstrates our continued investment in advancing the field

Freeslate, Inc., the leading provider of high throughput research solutions, today announced the launch of the CM Protégé PharmD System, part of the CM Protégé robotic platform family. The CM Protégé PharmD System is an automated platform for high throughput solid form and solubility screening. The system performs high throughput polymorph, salt, co-crystal, and solubility screens of active pharmaceutical ingredients (API).

As an essential part of drug development, solid form screening requires the study of a large number of parameters in order to identify the solid form with the optimal physical, chemical, and biopharmaceutical characteristics. Because doing such experimentation manually would be labor, time, and cost intensive, Freeslate now offers the CM Protégé PharmD System, bringing the benefits of high throughput solid and solubility screening to a broader range of researchers.

“The CM Protégé PharmD platform is the next evolution in our long history of providing systems for crystallization and solubility screens and demonstrates our continued investment in advancing the field,” said John S. Senaldi, President and CEO of Freeslate. “With the PharmD System, we are able to reach a broader customer base by offering an automation system designed specifically for solid form screening at a lower price point that still achieves the high level of throughput and ease of use for which Freeslate technologies are known.”

As a fully automated platform, the CM Protégé PharmD System can evaluate up to 384 crystallization conditions per run to rapidly turn around solid form screening projects, and users save valuable material through the system’s ability to utilize approximately 1 g of API per solid form screen. Solid forms can be analyzed by birefringence, x-ray powder diffraction, and Raman spectroscopy directly from the glass Universal Substrate of Freeslate’s Crystallization Assembly without any manual manipulation of fragile crystals. Heating, cooling, and mixing on-deck allows for simultaneous slurry, precipitation, cooling, and evaporation experiments on a single platform.

The CM Protégé PharmD System uses Freeslate’s Lab Execution and Analysis (LEA) software for library design, protocol development/execution, data analysis, and reporting. This allows users to design complex experiments quickly using its logical, recipe-oriented approach, and experimental conditions can be linked to analytical data for easy viewing and reporting.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mikelle Thatcher
Freeslate, Inc.
+1 (408) 773-4081
Email >
Visit website